Does the media favor AUTL or BHVN?

In the previous week, Autolus Therapeutics had 1 more articles in the media than Biohaven. MarketBeat recorded 2 mentions for Autolus Therapeutics and 1 mentions for Biohaven. Autolus Therapeutics' average media sentiment score of 0.55 beat Biohaven's score of -0.40 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AUTL or KOD?

In the previous week, Kodiak Sciences had 61 more articles in the media than Autolus Therapeutics. MarketBeat recorded 63 mentions for Kodiak Sciences and 2 mentions for Autolus Therapeutics. Kodiak Sciences' average media sentiment score of 0.59 beat Autolus Therapeutics' score of 0.55 indicating that Kodiak Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kodiak Sciences 17 Very Positive mention(s) 8 Positive mention(s) 25 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AUTL or NUVB?

In the previous week, Nuvation Bio had 6 more articles in the media than Autolus Therapeutics. MarketBeat recorded 8 mentions for Nuvation Bio and 2 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.55 beat Nuvation Bio's score of 0.33 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvation Bio 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer AUTL or ZBIO?

In the previous week, Zenas BioPharma had 10 more articles in the media than Autolus Therapeutics. MarketBeat recorded 12 mentions for Zenas BioPharma and 2 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.55 beat Zenas BioPharma's score of 0.40 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 1 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RXRX or AUTL?

In the previous week, Recursion Pharmaceuticals had 1 more articles in the media than Autolus Therapeutics. MarketBeat recorded 3 mentions for Recursion Pharmaceuticals and 2 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.55 beat Recursion Pharmaceuticals' score of 0.19 indicating that Autolus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Autolus Therapeutics (AUTL) Competitors

$1.78 -0.07 (-3.78%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.79 +0.01 (+0.56%)

As of 10/2/2026 07:30 PM Eastern

Compare

AUTL vs. BHVN, KOD, NUVB, ZBIO, and RXRX

Should you buy Autolus Therapeutics stock or one of its competitors? Autolus Therapeutics's main competitors and comparable companies include Biohaven (BHVN), Kodiak Sciences (KOD), Nuvation Bio (NUVB), Zenas BioPharma (ZBIO), and Recursion Pharmaceuticals (RXRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Autolus Therapeutics compare to Biohaven?

Autolus Therapeutics (NASDAQ:AUTL) and Biohaven (NYSE:BHVN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by company insiders. Comparatively, 13.8% of Biohaven shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Autolus Therapeutics has a beta of 2.15, indicating that its share price is 115% more volatile than the broader market. Comparatively, Biohaven has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market.

Autolus Therapeutics has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	6.28	-$287.53M	-$1.06	N/A
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A

Autolus Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 461.80%. Biohaven has a consensus price target of $18.69, suggesting a potential upside of 45.10%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Autolus Therapeutics is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86
Biohaven	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.59

Biohaven has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -238.66%. Autolus Therapeutics' return on equity of -178.66% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-238.66%	-178.66%	-49.34%
Biohaven	N/A	-1,328.94%	-138.27%

In the previous week, Autolus Therapeutics had 1 more articles in the media than Biohaven. MarketBeat recorded 2 mentions for Autolus Therapeutics and 1 mentions for Biohaven. Autolus Therapeutics' average media sentiment score of 0.55 beat Biohaven's score of -0.40 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biohaven	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Autolus Therapeutics beats Biohaven on 12 of the 15 factors compared between the two stocks.

How does Autolus Therapeutics compare to Kodiak Sciences?

Autolus Therapeutics (NASDAQ:AUTL) and Kodiak Sciences (NASDAQ:KOD) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Autolus Therapeutics has a beta of 2.15, suggesting that its stock price is 115% more volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.03, suggesting that its stock price is 103% more volatile than the broader market.

Kodiak Sciences has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -238.66%. Autolus Therapeutics' return on equity of -178.66% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-238.66%	-178.66%	-49.34%
Kodiak Sciences	N/A	-273.23%	-85.48%

In the previous week, Kodiak Sciences had 61 more articles in the media than Autolus Therapeutics. MarketBeat recorded 63 mentions for Kodiak Sciences and 2 mentions for Autolus Therapeutics. Kodiak Sciences' average media sentiment score of 0.59 beat Autolus Therapeutics' score of 0.55 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kodiak Sciences	17 Very Positive mention(s)	8 Positive mention(s)	25 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Autolus Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 461.80%. Kodiak Sciences has a consensus price target of $100.43, suggesting a potential upside of 6.33%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Autolus Therapeutics is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 44.4% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Kodiak Sciences has lower revenue, but higher earnings than Autolus Therapeutics. Kodiak Sciences is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	6.28	-$287.53M	-$1.06	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A

Summary

Autolus Therapeutics beats Kodiak Sciences on 9 of the 16 factors compared between the two stocks.

How does Autolus Therapeutics compare to Nuvation Bio?

Autolus Therapeutics (NASDAQ:AUTL) and Nuvation Bio (NYSE:NUVB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Autolus Therapeutics has a beta of 2.15, suggesting that its share price is 115% more volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market.

In the previous week, Nuvation Bio had 6 more articles in the media than Autolus Therapeutics. MarketBeat recorded 8 mentions for Nuvation Bio and 2 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.55 beat Nuvation Bio's score of 0.33 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvation Bio	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nuvation Bio has a net margin of -88.18% compared to Autolus Therapeutics' net margin of -238.66%. Nuvation Bio's return on equity of -46.59% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-238.66%	-178.66%	-49.34%
Nuvation Bio	-88.18%	-46.59%	-22.01%

72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by company insiders. Comparatively, 30.1% of Nuvation Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Nuvation Bio has lower revenue, but higher earnings than Autolus Therapeutics. Nuvation Bio is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	6.28	-$287.53M	-$1.06	N/A
Nuvation Bio	$62.90M	28.59	-$204.63M	-$0.44	N/A

Autolus Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 461.80%. Nuvation Bio has a consensus target price of $13.22, suggesting a potential upside of 158.20%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Autolus Therapeutics is more favorable than Nuvation Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Nuvation Bio beats Autolus Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Autolus Therapeutics compare to Zenas BioPharma?

Autolus Therapeutics (NASDAQ:AUTL) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Autolus Therapeutics has a beta of 2.15, meaning that its share price is 115% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.89, meaning that its share price is 189% less volatile than the broader market.

72.8% of Autolus Therapeutics shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Autolus Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 461.80%. Zenas BioPharma has a consensus target price of $46.71, indicating a potential upside of 65.07%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Autolus Therapeutics is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, Zenas BioPharma had 10 more articles in the media than Autolus Therapeutics. MarketBeat recorded 12 mentions for Zenas BioPharma and 2 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.55 beat Zenas BioPharma's score of 0.40 indicating that Autolus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Autolus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	1 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zenas BioPharma has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -238.66%. Zenas BioPharma's return on equity of -122.45% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Autolus Therapeutics	-238.66%	-178.66%	-49.34%
Zenas BioPharma	N/A	-122.45%	-58.04%

Autolus Therapeutics has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Autolus Therapeutics	$75.39M	6.28	-$287.53M	-$1.06	N/A
Zenas BioPharma	$1M	1,844.51	-$377.74M	-$8.99	N/A

Summary

Autolus Therapeutics beats Zenas BioPharma on 12 of the 17 factors compared between the two stocks.

How does Autolus Therapeutics compare to Recursion Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Autolus Therapeutics (NASDAQ:AUTL) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

In the previous week, Recursion Pharmaceuticals had 1 more articles in the media than Autolus Therapeutics. MarketBeat recorded 3 mentions for Recursion Pharmaceuticals and 2 mentions for Autolus Therapeutics. Autolus Therapeutics' average media sentiment score of 0.55 beat Recursion Pharmaceuticals' score of 0.19 indicating that Autolus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Autolus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 6.7% of Recursion Pharmaceuticals shares are owned by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Recursion Pharmaceuticals presently has a consensus price target of $8.06, suggesting a potential upside of 95.63%. Autolus Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 461.80%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Autolus Therapeutics is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

Recursion Pharmaceuticals has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.15, suggesting that its stock price is 115% more volatile than the broader market.

Autolus Therapeutics has higher revenue and earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	29.53	-$644.76M	-$1.04	N/A
Autolus Therapeutics	$75.39M	6.28	-$287.53M	-$1.06	N/A

Autolus Therapeutics has a net margin of -238.66% compared to Recursion Pharmaceuticals' net margin of -945.94%. Recursion Pharmaceuticals' return on equity of -50.41% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%
Autolus Therapeutics	-238.66%	-178.66%	-49.34%

Summary

Autolus Therapeutics beats Recursion Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get Autolus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AUTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AUTL vs. The Competition

Export

Metric	Autolus Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$492.40M	$3.87B	$7.14B	$13.17B
Dividend Yield	N/A	3.64%	2.53%	16.78%
P/E Ratio	-1.68	13.06	275.68	26.04
Price / Sales	4.04	1,374.07	658.29	101.16
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	2.66	16.63	10.93	6.31
Net Income	-$287.53M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-4.04%	-2.99%	-2.00%	-1.66%
1 Month Performance	-22.27%	-10.60%	-6.15%	-4.50%
1 Year Performance	10.56%	19.44%	7.44%	2.06%

Autolus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AUTL Autolus Therapeutics	3.3629 of 5 stars	$1.78 -3.8%	$10.00 +461.8%	+10.6%	$492.40M	$117.39M	N/A	752
BHVN Biohaven	2.4572 of 5 stars	$14.21 +4.3%	$18.69 +31.5%	-16.8%	$2.06B	N/A	N/A	274	Gap Up
KOD Kodiak Sciences	2.5481 of 5 stars	$32.42 -0.9%	$53.67 +65.5%	+603.3%	$2.06B	N/A	N/A	124	Trending News Analyst Forecast Insider Trade Analyst Revision
NUVB Nuvation Bio	2.7402 of 5 stars	$6.08 +3.9%	$13.00 +113.8%	+38.2%	$2.05B	$62.90M	N/A	305	News Coverage Analyst Forecast
ZBIO Zenas BioPharma	2.4392 of 5 stars	$32.55 +3.3%	$45.71 +40.4%	+35.1%	$2.05B	$10M	N/A	167	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AUTL) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Autolus Therapeutics (AUTL) Competitors

AUTL vs. BHVN, KOD, NUVB, ZBIO, and RXRX

How does Autolus Therapeutics compare to Biohaven?

Summary

How does Autolus Therapeutics compare to Kodiak Sciences?

Summary

How does Autolus Therapeutics compare to Nuvation Bio?

Summary

How does Autolus Therapeutics compare to Zenas BioPharma?

Summary

How does Autolus Therapeutics compare to Recursion Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL vs. The Competition

Autolus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Autolus Therapeutics (AUTL) Competitors

AUTL vs. BHVN, KOD, NUVB, ZBIO, and RXRX

How does Autolus Therapeutics compare to Biohaven?

Do insiders & institutionals hold more shares of AUTL or BHVN?

Which has more volatility & risk, AUTL or BHVN?

Which has better valuation & earnings, AUTL or BHVN?

Do analysts prefer AUTL or BHVN?

Is AUTL or BHVN more profitable?

Does the media favor AUTL or BHVN?

Summary

How does Autolus Therapeutics compare to Kodiak Sciences?

Which has more volatility & risk, AUTL or KOD?

Is AUTL or KOD more profitable?

Does the media favor AUTL or KOD?

Do analysts recommend AUTL or KOD?

Do insiders and institutionals hold more shares of AUTL or KOD?

Which has better valuation and earnings, AUTL or KOD?

Summary

How does Autolus Therapeutics compare to Nuvation Bio?

Which has more risk & volatility, AUTL or NUVB?

Does the media prefer AUTL or NUVB?

Is AUTL or NUVB more profitable?

Do institutionals & insiders have more ownership in AUTL or NUVB?

Which has higher earnings and valuation, AUTL or NUVB?

Do analysts prefer AUTL or NUVB?

Summary

How does Autolus Therapeutics compare to Zenas BioPharma?

Which has more risk & volatility, AUTL or ZBIO?

Do insiders and institutionals believe in AUTL or ZBIO?

Do analysts recommend AUTL or ZBIO?

Does the media prefer AUTL or ZBIO?

Is AUTL or ZBIO more profitable?

Which has preferable valuation and earnings, AUTL or ZBIO?

Summary

How does Autolus Therapeutics compare to Recursion Pharmaceuticals?

Does the media refer more to RXRX or AUTL?

Do insiders & institutionals hold more shares of RXRX or AUTL?

Do analysts recommend RXRX or AUTL?

Which has more risk and volatility, RXRX or AUTL?

Which has higher earnings & valuation, RXRX or AUTL?

Is RXRX or AUTL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUTL vs. The Competition

Autolus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools